Pharmaceutical

Eisai and Biogen launch LEQEMBI for Alzheimer’s in China

Eisai and Biogen have announced the introduction of LEQEMBI (lecanemab) for the treatment of Alzheimer's disease (AD) in China.

Jun 30, 2024 - 04:00
Eisai and Biogen launch LEQEMBI for Alzheimer’s in China
Eisai and Biogen have announced the introduction of LEQEMBI (lecanemab) for the treatment of Alzheimer's disease (AD) in China.
Read the original article

Tags:

Previous Article

Holoclara gains Series A financing for worm-derived therapies

Next Article

AI Firm Formation Bags $372 Series D Funding

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: Gain-of-function research is about much more than dangerous pathogens

Opinion: Gain-of-function research is about much more t...

Jul 22, 2023

AI insight at BIO, Google and Mayo Clinic’s latest effort, & $13 million for health workforce tech

AI insight at BIO, Google and Mayo Clinic’s latest effo...

Jun 8, 2023

Delivery and manufacturing hurdles remain in the cell and gene therapy

Delivery and manufacturing hurdles remain in the cell a...

Mar 22, 2024